← Eichor
Study identifier: NCT06809075 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Immunological Reset to Allow Access to HLA Compatible Transplantation in Highly Sensitized Kidney Transplant Candidates Through Non-myeloablative Autologous Stemm Cell Transplantation

Condition: Kidney Disease · Kidney Transplant · Kidney Transplant Candidates  ·  Sponsor: Hospital Universitari Vall d'Hebron Research Institute

PhaseNA
Planned participants10
Who can joinAll sexes, 18 Years to 65 Years
Healthy volunteersNo

About this study

This is a study for hypersensitized patients who have been waiting for more than 3 years for an offer for a kidney transplant. The objective is to perform a transplant of autologous hematopoietic precursors with the aim of producing what we call an immunological reset to make the maximum number of anti-HLA antibodies disappear and thus increase the chances of the patient receiving an offer for a kidney transplant.

This description comes directly from the study's public registry record.

Talk to the study team

Oriol Bestard, MD, PhD  ·  932746000  ·  oriol.betsard@vallhebron.cat

Delphine Kervella, MD, PhD  ·  932746000  ·  delphine.kervella@vallhebron.cat

Always discuss trial participation with your own doctor first.

Locations (1)

Hospital Universitari Vall d'HebronBarcelona, SpainRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06809075